<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04608864</url>
  </required_header>
  <id_info>
    <org_study_id>008-2020</org_study_id>
    <nct_id>NCT04608864</nct_id>
  </id_info>
  <brief_title>Varicocele Repair for Men Undergoing IVF/ICSI</brief_title>
  <acronym>Varicocele</acronym>
  <official_title>Varicocele Repair for Infertile Men Undergoing IVF/ICSI: a Parallel, Two-group, Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Al-Yasmeen Fertility and Gynecology Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Elite Fertility and Gynecology Center, Cairo, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Banon IVF Center Assiut, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IbnSina IVF Center, Sohag, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qena IVF Centre, Qena, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amshaj IVF Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Al-Yasmeen Fertility and Gynecology Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For infertile men undergoing intracytoplasmic sperm injection (ICSI), data from retrospective&#xD;
      studies suggested that varicocele repair may be beneficial and associated with improved&#xD;
      livebirth and pregnancy rates, however, its role remains uncertain and disputed. To date, the&#xD;
      investigators are not aware of published randomized controlled trail (RCT) that have&#xD;
      evaluated whether varicocele repair would improve ICSI outcomes on patients with male-factor&#xD;
      infertility.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Varicocele repair in the era of assisted reproductive technology (ART) has been a point of&#xD;
      dispute. The American Society for Reproductive Medicine (ASRM) Practice Committee recommended&#xD;
      has considered ART as a primary treatment for female factor, regardless of the presence of&#xD;
      varicocele and abnormal semen parameters.&#xD;
&#xD;
      A systematic review of 7 studies involving 1,241 men with a clinical varicocele and abnormal&#xD;
      semen parameters showed improved livebirth and pregnancy rates after varicocelectomy in&#xD;
      infertile men undergoing IVF/ICSI. Studies included in this systematic review were&#xD;
      retrospective nature with a considerable heterogeneity. Evidence to support varicocelectomy&#xD;
      for men with abnormal semen analysis undergoing IVF/ICSI has therefore remained inconclusive.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Livebirth rate</measure>
    <time_frame>up to 37 weeks</time_frame>
    <description>the percentage of women who underwent randomization and will have a livebirth after at least 37 completed weeks of gestation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical pregnancy</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>positive βhCG ≥10 IU/L at 14 days after egg retrieval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy</measure>
    <time_frame>up to 7 weeks</time_frame>
    <description>registered sacs with a heartbeat on ultrasound &gt;7th week of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy</measure>
    <time_frame>up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriage</measure>
    <time_frame>up to 20th weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stillbirth</measure>
    <time_frame>up to 20 weeks</time_frame>
    <description>intrauterine death at &gt;20 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilization rate</measure>
    <time_frame>up to 16-18 hours after ICSI</time_frame>
    <description>number of oocytes fertilized per oocytes retrieved</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Top quality embryos</measure>
    <time_frame>up to 3 days after ICSI</time_frame>
    <description>number of top quality embryos at Day 3 per number of fertilized oocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cryopreservation rate</measure>
    <time_frame>up to 3-6 days after ICSI</time_frame>
    <description>number of embryos cryopreserved per randomized woman</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blastocyst formation rate</measure>
    <time_frame>up to 5 or 6 days after ICSI</time_frame>
    <description>number of blastocyst at Day 5 or 6 per number of fertilized oocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>implantation rate</measure>
    <time_frame>up to 7 weeks</time_frame>
    <description>number of intrauterine gestational sacs detected by ultrasound over the total number of embryos transferred</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Infertility, Male</condition>
  <arm_group>
    <arm_group_label>varicocelectomy arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The varicocelectomy procedure will be performed three months before ICSI for men with with male-factor infertility and were diagnosed clinically with varicocele</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (No varicocelectomy) arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Couples with male-factor infertility and males were diagnosed clinically with varicocele will undergo ICSI</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>varicocelectomy</intervention_name>
    <description>microsurgical subinguinal varicocelectomy</description>
    <arm_group_label>varicocelectomy arm</arm_group_label>
    <other_name>varicocele repair</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Couples able to provide informed consent.&#xD;
&#xD;
          2. Couples with at least 12 months of infertility&#xD;
&#xD;
          3. Couples with male-factor infertility&#xD;
&#xD;
          4. Couples counseled for ICSI procedure by reproductive specialist.&#xD;
&#xD;
          5. Couples undergoing their first ICSI cycle or their second ICSI cycle after a&#xD;
             previously successful treatment.&#xD;
&#xD;
          6. Female: age between 18-43; body mass index (BMI) between 19.0-35.0 kg/m2; FSH level&#xD;
             3.0-20.0 miU/mL and/or AMH ≥1.5 pmol/L; with regular menstrual cycles (defined as 25&#xD;
             to 35 days in duration), evidence of ovulation (by biphasic basal body temperature,&#xD;
             ovulation predictor kits, or luteal serum progesterone level ≥3 ng/mL), have no&#xD;
             uterine abnormality by ultrasound; anticipated normal responder (≥5 antral follicle&#xD;
             count or ≥5.4 pmol/L Anti- mullerian hormone (AMH).&#xD;
&#xD;
          7. Male: age: 18-55; able to produce freshly ejaculated sperm for the treatment cycle;&#xD;
             diagnosed with clearly palpable varicocele; have at least one abnormal semen parameter&#xD;
             on a semen analysis in the preceding 3 months: sperm concentration ≤15 million/mL&#xD;
             (oligospermia), total motility≤40% (asthenospermia), or normal morphology ≤4%&#xD;
             (teratospermia); normal hormonal profile&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who willing to undergo ICSI with preimplantation genetic diagnosis.&#xD;
&#xD;
          2. Female: have previous two cycles of implantation failure at fresh transfer; with&#xD;
             unilateral oophorectomy; PCOs; have any uterine pathology (myomas, adenomyosis,&#xD;
             endocrinopathies, thrombophilia, chronic pathologies, acquired or congenital uterine&#xD;
             abnormalities); have severe endometriosis; have uni- or bilateral hydrosalpinx; have&#xD;
             history of recurrent pregnancy loss, takes any medical condition that affect&#xD;
             fertility.&#xD;
&#xD;
          3. Male: have varicocele associated with hydrocele or inguinal hernia; secondary and&#xD;
             recurrent varicocele, varicocele complicated by thrombophlebitis; varicocele with&#xD;
             infertility due to other causes (demonstrated by andrologists), if they have a sperm&#xD;
             concentration &lt;1 million/mL on the screening semen analysis or if they were taking&#xD;
             fertility medication or testosterone. Men are required to refrain from taking any&#xD;
             medications for 4 weeks before randomization.&#xD;
&#xD;
          4. Abnormal karyotyping for female or male partners.&#xD;
&#xD;
          5. Uncontrolled diabetes, liver or renal disease, history of malignancy or borderline&#xD;
             pathology of male or female partners.&#xD;
&#xD;
          6. Previous participation in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Fawzy, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>IbnSina IVF Center, IbnSina Hospital, Sohag</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed Fawzy, Ph.D</last_name>
    <phone>+201011122286</phone>
    <email>drfawzy001@me.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yasmin Magdi</last_name>
    <phone>+201282313979</phone>
    <email>Yas.magdi@hotmail.com</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Kohn TP, Kohn JR, Pastuszak AW. Varicocelectomy before assisted reproductive technology: are outcomes improved? Fertil Steril. 2017 Sep;108(3):385-391. doi: 10.1016/j.fertnstert.2017.06.033. Review.</citation>
    <PMID>28865536</PMID>
  </results_reference>
  <results_reference>
    <citation>Kirby EW, Wiener LE, Rajanahally S, Crowell K, Coward RM. Undergoing varicocele repair before assisted reproduction improves pregnancy rate and live birth rate in azoospermic and oligospermic men with a varicocele: a systematic review and meta-analysis. Fertil Steril. 2016 Nov;106(6):1338-1343. doi: 10.1016/j.fertnstert.2016.07.1093. Epub 2016 Aug 12. Review.</citation>
    <PMID>27526630</PMID>
  </results_reference>
  <results_reference>
    <citation>Practice Committee of the American Society for Reproductive Medicine; Society for Male Reproduction and Urology. Report on varicocele and infertility: a committee opinion. Fertil Steril. 2014 Dec;102(6):1556-60. doi: 10.1016/j.fertnstert.2014.10.007. Epub 2014 Nov 25.</citation>
    <PMID>25458620</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 11, 2020</study_first_submitted>
  <study_first_submitted_qc>October 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2020</study_first_posted>
  <last_update_submitted>October 28, 2020</last_update_submitted>
  <last_update_submitted_qc>October 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Al-Yasmeen Fertility and Gynecology Center</investigator_affiliation>
    <investigator_full_name>Yasmin Magdi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Varicocele</mesh_term>
    <mesh_term>Infertility, Male</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>3-6 months</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

